The combination regimen of a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and endocrine therapy (e.g., an aromatase inhibitor) is the current first-line standard-of-care treatment for patients with metastatic ER+/HER2– breast cancer [6]. This evidence concerns the gene ERBB2 and breast cancer.